MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$213M+1353.8% YoY

Gross Profit

$204M95.7% margin

Operating Income

-$47M-22.2% margin

Net Income

-$42M-19.9% margin

EPS (Diluted)

$-1.90

QoQ Revenue Growth

+55.0%

Cash Flow

Operating Cash Flow

-$47M

Free Cash Flow

-$47M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$319M

Stockholders' Equity

$696M

Cash & Equivalents

$186M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$213M	$15M	+1353.8%
Gross Profit	$204M	$14M	+1355.1%
Operating Income	-$47M	-$163M	+71.0%
Net Income	-$42M	-$152M	+72.2%

Revenue Segments

Reportable Segment

$213M100%

MDGL Q2 2025 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena